SEARCH

SEARCH BY CITATION

Fig. S1. Cluster analysis of microRNAs differentially expressed between de novo DLBCL cases with a GC- and NGC-immunophe-notype.

Fig. S2. Kaplan-Mier survival curve of EFS in DLBCL patients based on GC- or NGC-immunophenotype. Curves were compared by univariate (log-rank) analysis.

Fig. S3. Kaplan-Mier survival curve of EFS in DLBCL patients based on IPI status. Curves were compared by univariate (log-rank) analysis.

Fig. S4. Cluster analysis of microRNAs associated with IPI status in DLBCL.

Fig. S5. Expression levels of microRNAs differentially expressed between FCL-t and FCL-nt cases. P-values were calculated by independent t-test.

Table S1. Summary of DLBCL de novo patient details for whom clinical details were available (n= 61).

Table S2. MicroRNAs differentially expressed (P < 0.05) between DLBCL (DLBCL de novo and DLBCL-t) and FCL (FCL-nt and FCL-t) diagnoses.

Table S3. MicroRNAs differentially expressed (P < 0.05) between FCL cases that subsequently underwent high-grade transformation (FCL-t) and those that did not (FCL-nt). Median follow-up time 60 months (range 52–132 months).

Please note: Wiley-Blackwell are not responsible for the content or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.

FilenameFormatSizeDescription
JCMM_628_sm_FigS1-S2.doc1771KSupporting info item

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.